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Abstract
Background: Iodine is a key component of thyroid hormones that are critical for normal development of the brain
and nervous system in utero. Recent results indicate that two thirds of pregnant women in Europe have sub-optimal
iodine nutrition. In Norway, milk and seafood are the most important dietary iodine sources and contributes to about
80% of the intake.
Method: Two-armed randomized trial where 137 pregnant women were randomized to either receiving cod twice
weekly, or continue with habitual diet for 16 weeks (pregnancy week 20–36). Socioeconomic- and demographic factors,
dietary information and biological (urine, blood, and hair) samples are collected pre- and post-intervention, and at six
weeks, three-, six-, and eleven months postpartum. Biological samples (urine, blood, and hair) of the infant are collected
at six weeks, three-, six-, and eleven months postnatal. Child development is assessed by The Bayley Scale of Infant and
Toddler Development, 3rd edition, at eleven months, and by parent report on the Ages and Stages Questionnaire, 3rd
edition, and Ages and Stages Questionnaire: Social Emotional at three-, six-, and eleven months.
Discussion: The Mommy’s Food study will provide knowledge on changes in iodine nutrition when consuming iodine
rich fish during pregnancy and contribute to the understanding of the impact of iodine status in pregnancy on infant
neurodevelopment.
Trial registration: This study is registered in ClinicalTrials.gov (NCT02610959). Registered November 17, 2015.
Keywords: Iodine intake, Iodine status, UIC, Maternal diet, Nutritional status, Fish, Neurodevelopment, Bayley scales of
infant and toddler development, RCT, Pregnancy, Infant nutrition
Background
Iodine is an essential nutrient for the synthesis of
thyroid hormones triiodothyronine (T3) and thyroxine
(T4). Dietary iodine is rapidly absorbed through the
stomach and duodenum, and the thyroid gland is
dependent on regular and adequate supply through the
diet in order to produce these vital thyroid hormones.
Thyroid hormones are involved in a range of biochem-
ical processes, including regulation of metabolic rate,
energy production, protein and enzyme synthesis,
thermoregulation, growth and neural development [1].
The iodine requirement during pregnancy is greatly in-
creased because the mother synthesizes approximately
50% more T4 to maintain maternal euthyroidism and to
transfer thyroid hormones to the fetus prior to gesta-
tional week 20, and because iodine needs to be trans-
ferred to the fetus for fetal thyroid hormone production
post gestational week 20. In addition, the renal iodine
clearance increases during pregnancy. Thus, it is impor-
tant for pregnant women to consume sufficient iodine
during pregnancy [1].
* Correspondence: maria.wik.markhus@hi.no
1Institute Institute of Marine Research, PO Box 1870, Nordnes, 5817 Bergen,
NO, Norway
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Markhus et al. BMC Nutrition  (2018) 4:7 
https://doi.org/10.1186/s40795-018-0215-1
In general, we have limited dietary iodine sources and
the iodine content of terrestrial foodstuffs is much lower
compared to marine foodstuffs. The only good natural
source of iodine is seawater fish and other marine pro-
ducts [2]. Iodized salt is the most important source
worldwide and is also the agreed strategy for achieving
iodine sufficiency [2]. In Norway, iodized salt contributes
insignificantly as the maximum level of iodine added to
salt is 5 μg/g, and the food industry is not permitted to
use iodized salt.
Pregnant and lactating women are vulnerable groups
in terms of developing iodine deficiency since they have
higher needs of iodine [2, 3]. This has been confirmed in
the most recent data from the Norwegian Mother and
Child Cohort Study (MoBa) (n = 61,904), demonstrating
inadequate iodine intake in the majority of pregnant
Norwegian women. The median iodine intake was 141
μg/day from food and 166 μg/day from food and sup-
plements. Only 21.7% reach the recommended daily
intake by WHO/UNICEF/ICCIDD of 250 μg iodine/
day, and the study concludes that suboptimal iodine
intake among Norwegian pregnant women is a health
concern [4]. Determination of iodine status by urinary
iodine concentration (UIC) in a sub-study of the
MoBa (n = 119) was in line with the findings from the
dietary study [4], and insufficient iodine status has
also been demonstrated in other studies among
Norwegian pregnant women [5, 6].
Inadequate iodine status in pregnancy has been as-
sociated with suboptimal cognitive outcomes in the
children at eight years of age in observational studies
[7]. This in line with the MoBa study where maternal
iodine intakes below the Estimated Average Require-
ments (160 μg/d) during pregnancy was associated
with child language delay, impaired fine motor skills
and mental health problems at three years of age, but
no associations with gross motor skills as measured
[8]. Interestingly, the results showed no evidence of a
protective effect of iodine supplementation during
pregnancy on child development. Few intervention
studies on maternal iodine supplementation on child
development exist and the quality of the existing
studies are poor, as concluded in a recent review [9].
To our knowledge, this is the first trial intervening
pregnant women with iodine rich foods (cod), to
study its effects on maternal iodine status and infant
development.
Methods/design
The overall aims of this trial are to investigate, in a ran-
domized controlled trial (RCT), if an increased intake of
cod in pregnancy has an impact on (1) maternal iodine
status and (2) infant development.
Trial design
The study is a two-armed randomized controlled inter-
vention trial involving cod intake in pregnancy with the
primary purpose of prevention. The ideal control would
be pregnant women from the same trial whom were to
be instructed to continue with their habitual diet with
restriction to include iodine. For ethical reasons the con-
trol is pregnant women, within the same trial, who will
continue with their habitual diet. The primary outcome
is UIC measured at post intervention (gestational week
36), and the secondary outcome is neurodevelopment
assessed by the cognitive, language and motor scales of
the Bayley Scales of Infant and Toddler Developmental
3rd edition (Bayley-III) when the infants are 11 months
of age. Other outcomes include urine samples, dietary
data and blood samples from the mother and from the
infant, as well as data on child development such as de-
velopmental status, socio-emotional abilities and infant
sleep, and maternal mental health, that will be collected
at several time points during the first year of life.
Study setting and recruitment
Participants were recruited through the Women’s clinic
at Haukeland University Hospital in Health region west
in Norway. Approximately 5000 women give birth at the
Women’s Clinic every year, which is the local hospital
for the population in Bergen and surrounding areas.
From January 2016 until February 2017, information re-
garding the intervention trial was included in the postal
mail, sent from the Women’s Clinic, with the date/time
for the routine ultrasound (RU). In Norway, the RU
takes place in gestational week 17–19. To ensure
sufficient participants information regarding the trial
and invitation to participate was also broadcasted online
(Facebook, Instagram, and magazine for pregnant in
Norway). Pregnant women who were interested in the
study contacted the secretariat. Time schedule of
enrolment, interventions, assessments, and all visits for
participants is schematically diagrammed in Fig. 1.
Eligibility criteria
Inclusion criteria: prim parous singleton pregnancy ≤ ges-
tational week 19, Norwegian speaking and/or understand
Norwegian writing (all validated tests of the child will be
in Norwegian). Exclusion criteria: allergies to fish, chronic
diseases known to affect iodine status (Graves’ disease,
Thyroiditis, Thyroid Nodules, known hypothyroidism or
hyperthyroidism).
Randomization, allocation and blinding
Randomization will be performed individually by lottery
at the second visit in gestational week 19 in blocks of 10
to ensure approximately equal allocation to the two
study groups. Study investigators will enroll participants,
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generate the allocation, and randomly assign participants
to interventions after baseline sampling. The study id-
number for each participant will be a random number
between 1 and 200. By this procedure, participants and
investigators will be blinded to the allocation until the
baseline sampling has been completed. Owing to the na-
ture of the intervention, blinding of the participating
mothers will not be possible. However, the infants will
be blinded throughout the trial and data analysis and
study investigators and laboratory personnel will be
blinded when analyzing data.
Dietary intervention
Study foods and instructions
Participants in the intervention group will receive fro-
zen cod fillets (Lerøy A/S, Bergen, Norway) and are
asked to consume two intervention meals of 200 g
weekly (a total of 400 g cod per week). They will
prepare the dinner meal themselves and are free to
choose recipes. However, they will be provided with
recipes that could be used ad libitum. For compliance
purposes, participants will be instructed to weigh
(Kitchen Scale, article no. 34–1207-16, ClasOhlson.-
com) the cod fillet before preparing the meal, and
weigh the fillet leftovers (if any), after the meal is
completed. The participants will record these data, in
addition to receipt used and date of consumption, in
a weight registration form. These data will be used in
order to calculate iodine intake from the intervention
meal. The participants in the control group will be
instructed to follow their habitual diet. Once a preg-
nant woman is enrolled or randomized, the study in-
vestigators will make every reasonable effort to follow
the participant for the entire study period. Prior to all
the visits, the participants will be reminded about the
upcoming appointment. Study investigators will
Fig. 1 Overview of study schedule and main activities. *Six consecutive days between GW 18 and GW 19 and between GW 35 and GW 36 (last
days of intervention meal). †Questionnaire includes: participant characteristics; self-reported maternal mental health; and parent-reported infant
mental health. Abbreviations: GW, gestational week; M, mother; I, infant; U, urine; S, serum; T4, thyroxine; T3, triiodothyronine; RBC, red blood cells;
FA, fatty acids; H, hair; FFQ, Food Frequency Questionnaire; ASQ-3, The Ages and Stages Questionnaire; ASQ:SE, The Ages and Stages Question-
naire: Social Emotional; BISQ, Brief Infant Sleep Questionnaire; EPDS, The Edinburgh Postnatal Depression Scale; HADS, The Hospital Anxiety and
Depression Scale. ‡Screening tool for eating disorders
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always take into account the participants’ private
calendar in the attempt to best ensure retention.
Safety of foods
Women in the intervention group will have an intake of
(0.4 kg cod per week * 0.04 mg Hg/kg *1000=) 16 μg
mercury (Hg) per week from the study diet. Weekly in-
take of dioxin and dioxin-like polychlorinated biphenyls
(dl-PCBs) will be (0.4 kg per week *0.08 ng toxic equiva-
lences (TEQ) /kg* 1000=) 32 pg TEQ per week. The
CONTAM panel in the European Food Safety Authority
(EFSA) established a tolerable weekly intake (TWI) for
organic Hg of 1.3 μg/kg bodyweight. This is in accor-
dance with the Joint FAO/WHO expert Committee on
Food additives (JECFA) [10]. The equivalent TWI for di-
oxin and dl-PCB is 14 pg TEQ per kilo bodyweight [11].
For the participants in the study, their TWI is calculated
based on the 5-percentile weight of the women in the
Little in Norway cohort, n = 828 (unpublished data) (5
percentile = 56 kg). That means that they have a TWI of
71.2 μg Hg per week and 784 pg TEQ for dioxin and dl-
PCBs. Thus, the intake of Hg and dioxins and dl-PCBs
will be maximum 22% and 4% of the TWI. Conse-
quently, the intake of cod in this study is far below the
TWI for this especially vulnerable population.
Assessment and data collection
Biological samples-urine
Participants will receive six marked tubes for collection
of urine in gestational week 18–19 and in week 35–36
together with instructions on how to collect the spot
urine samples. A pooled sample of 1 ml of homogenized
spot urine collected on six consecutive days, between
4 pm and midnight, will be analyzed for iodine pre- and
post intervention in both groups. The participants will
keep the urine samples in their home freezer until the
visits in gestational week 19 and 36. At this visits at
three and six months postpartum, the mothers will
deliver a spot urine sample. For the infants, urine collec-
tion pads will be placed in the diapers 1–2 h before the
visit for urine sampling, and extracted at the visit at
three-, six and eleven months. The urine samples will be
transferred to cryo tubes and stored at minus 20 °C
pending analysis by inductively coupled plasma mass
spectrometry (ICP-MS). Method description of UIC (μg/
L) determination is previously described by Dahl et al.
[12]. Urinary creatinine concentration (g/L) will be ana-
lyzed using MAXMAT PL II multidisciplinary diagnostic
platform with a creatinine PAP kit [13].
Biological samples-blood
Pre- and post-intervention blood sampling (gestational
week 18 and 36) will include thyroid hormone status
(thyroid stimulating hormone (TSH), free T3, free T4),
fatty acid status, iron status and vitamin B12 status. The
same blood sampling will be conducted in mothers and
infants at three- and six months postpartum. Venous
blood for serum preparation will be collected in BD
Vacutainer® SST™ vials II Advanced and set to coagulate
for minimum 30 min before centrifuging (1000–1300 G,
20 °C, 10 min) within 60 min. Venous blood for plasma
preparation will be collected in BD Vacutainer® K2E
5.4 mg (adults) and 3.6 mg (infants) vials and centri-
fuged (1000–1300 G, 20 °C, 10 min) within 30 min, for
the preparation of erythrocytes. Erythrocytes will be ad-
equately separated from plasma and the layer on top of
the cells (buffy coat) to ensure a clean erythrocyte
fraction. In cases were venipuncture of infants will be
problematic, capillary blood will be collected from the
heel or a fingertip, depending on age/weight. Prior to ca-
pillary blood sampling, the heel or finger will be warmed
with a hot water balloon to ensure vasodilation to enable
sufficient blood flow. Tenderfoot ITC® heel incision
devise will be used for heel pricks and ACCU-CHEK®
Safe-T-Pro Plus lancet will be used for finger pricks.
Blood samples will be stored at minus 80 °C, pending
analysis. TSH, free T3, and, free T4 will be analyzed in
serum using magnetic separation and detected by chemi-
luminescence labeled with acridinum ester on an Advia
Centaur XPT (Siemens Healthcare diagnostics Inc.,
Tarrytown, USA). Ferritin will be analysed by an immu-
noturbidimetric method using Advia Chemistry XPT
(Siemens Mediacal Solutions Diagnostica, Japan). Fatty
acids will be analyzed in red blood cells by standardized
procedures at Institute of Marine Research (IMR) [14],
using ultrafast gas chromatographic (UFGC) (Thermo
Electron Corporation, Massachusetts, USA). In case of
advances concerning biomarkers of the primary or
secondary outcome variable, other analysis than those
already mentioned will be considered. This includes
single nucleotide polymorphisms (SNPs) analyses from
buffy coat.
Biological samples-breastmilk
At six weeks and three months postpartum, the mothers
are requested to sample breastmilk or formula. The
breastmilk or formula will be analyzed for iodine content
and fatty acids. Participants will receive instructions and
six marked cryo tubes for collection of breastmilk at the
start, during and the end of a chosen feed for two days.
If the mother is not breastfeeding, she will prepare a
meal of the given formula and collect in two tubes for
two days. Mothers will be instructed to record date and
time of sampling, and store the samples in their home
freezer pending pick-up from study investigators
(samples from six weeks postpartum) or submission of
samples at the three months follow up visit. For submis-
sion of samples, the participants will receive freezer
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packs for transportation. The samples will be stored at
minus 80 °C pending analysis for iodine concentration
on ICP-MS, previously described by Dahl et al. [15], and
fatty acids by standardized procedures at IMR [14], using
ultrafast gas chromatographic (UFGC) (Thermo Electron
Corporation, Massachusetts, USA).
Biological samples-hair
Hair samples will be collected for mercury analysis from
the mothers in gestational week 18 and 36, and at six
months postpartum, and from infants at age six weeks,
six- and eleven months. Mothers following instructions
at age six weeks, will perform hair collection from in-
fants. Samples are obtained from the mothers and in-
fants by cutting a hair-bundle with an approximate
diameter of 2–5 mm, as close to the scalp as possible
from the occipital area of the head. A thin thread will
be tied closest to the end nearest the scalp. Hair
samples will be stored in room temperature pending
analysis using Direct Mercury Analyser (DMA-80,
Milestone) [16].
Dietary intake
A structured 6-days food diary (FD), developed for this
study with the purpose to estimate maternal iodine in-
take, will be handed out at the first visit, in gestational
week 18, and mailed by post to be filled out in gesta-
tional week 35. The habitual diet of both intervention
and control group is reported in a short Food Frequency
Questionnaire (FFQ) in gestational week 18 and 35, and
three-, six, and eleven months postpartum. The FFQ
captures iodine rich foodstuff (seafood, milk, dairy, eggs
and supplements), is based on a validated short seafood
FFQ developed to analyze food habits in pregnant and
postpartum women [17].
Infant’s dietary intake will be collected through non-
validated FFQ’s (custom to the infants’ age) at three-,
six- and eleven months of age. In addition, a 24-h diet
recall interview will be conducted at the three- and six
months’ visit. The mothers will be asked what the infant
has ingested during the last 24 h. In cases of non-report
of supplement intake, the mothers will actively be asked
if the infant has been given any dietary supplements.
Infant development
At eleven months, the children will be assessed with the
Bayley-III by trained study investigators. The Bayley-III
is a comprehensive assessment tool of neurodevelop-
ment administered directly with the child. The tool in-
cludes three main subscales; the cognitive, language
(receptive and expressive) and motor (fine and gross
motor) scale. The Bayley-III represents the gold standard
of developmental assessments in this age group and is
widely used as an outcome measure in clinical trials.
Two testers will administer the Bayley-III after undergo-
ing training by a clinical child psychologist and a
neuropsychologist. Standardization exercises will be con-
ducted measuring the inter-rater reliability of the asses-
sor compared with a gold standard until satisfactory
level of agreement. During the trial, 10% of the tests will
be double scored, and inter-rater agreement will be
assessed to ensure high quality testing.
In addition, child development will be measured at
three-, six- and eleven months by The Ages and Stages
questionnaire, 3rd edition (ASQ-3) [18]. The ASQ-3 is
an age-specific parent-reported screening questionnaire
consisting of 30 items covering five developmental
domains and has five subscales: communication, fine-
motor, gross-motor, problem-solving, and personal-
social. The scale has been translated and validated to a
Norwegian setting [19].
Infant mental health and sleep
Measures in infant socio-emotional abilities and sleep is
included in the electronic questionnaires at three- six-,
and eleven months postpartum. Socio-emotional abilities
will be measured by The Ages and Stages Questionnaire:
Social Emotional (ASQ:SE) [20]. The ASQ:SE is a short
parent-reported questionnaire on social and emotional
development in children, which has demonstrated good
psychometric properties in the United States [21] and
Norway [19]. Infant sleep is measured by the Brief Infant
Sleep Questionnaire (BISQ). BISQ is a short questionnaire
on infant sleep that has demonstrated good psychometric
properties as a sleep screening tool for clinical and
research purposes in infants and toddlers [22].
Maternal self-reported mental health.
Data regarding maternal self-reported mental health is
included in the electronic questionnaires pre- and post-
intervention (gestational week 18 and 36, respectively),
three- six-, and eleven months postpartum. Mothers will
be asked questions regarding sleep duration and insom-
nia symptoms. The Relationship Satisfaction Scale [23]
will be used to measure relationship satisfaction. The
Edinburgh Postnatal Depression Scale (EPDS) [24] is in-
cluded as a screening for postnatal depression, and the
Hospital Anxiety and Depression Scale (HADS) [25] is
included as a screening for anxiety and depression. And
finally, the SCOFF questionnaire will be used to screen
for eating disorders among the mothers [26].
Data management and biobank
All collected data will at all times be treated strictly con-
fidential and data will only be used pseudonymized for
all evaluations. The protocols and questionnaires from
the cognitive assessments will be administered at Uni
Research Health. Scoring of the protocols will be done
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on a secure computer, and the protocols and ques-
tionnaires will be kept in a locked and secure cabinet
particular for this project. Data will be entered in
UHeads, a secure research server that holds optimal
standards for storage of clinical data. The data from
the 6-d dietary record and weight form, filled out by
participants, will be entered into SPSS by non-study
investigators and quality checked by double entry of
10%. In case of a mismatch, the paper forms will be
used to correct the data entry error. The data will
not be publicly available to ensure participant confi-
dentiality in accordance with the ethical clearance.
After data entry and coding, a cleaned dataset of all
combined data will be stored in an SPSS database on
a secure server with access limited to the principal
investigators. Prior to any data analysis, the Mommy’s
Food project group must approve an application of
data utilization and intended authorship. To ensure
confidentiality, data will be blinded of any identifying
participant information if dispersed to non-project
team members. Author eligibility guidelines will ad-
here to the Norwegian national standards for research
ethics [27].
Biological samples collected and information derived
from this material will be stored in a specific research
biobank at IMR. Participants in the study also consent
to the inclusion of the biological material and analytical
results in the biobank. Last author (MK) is responsible
for the research biobank. The biobank is scheduled to
expire in 2025. After that, data material will be anon-
ymized. The biological material may only be used after
approval by the Regional Committee for Medical and
Health Research Ethics (REK).
Statistical considerations
Sample size calculation
A sample size of 60 women/group will have a 95% power
to detect a 30% higher UIC in the intervention group
compared to the control group (i.e., median UIC of ̴120
μg/L compared with 80 μg/L. A total sample size of 144,
divided into two groups, is anticipated, taken into ac-
count a 20% drop out rate. Data from the “Little in
Norway” cohort has been applied in the power calcula-
tion of sample size. The following simplified equation
has been used to calculate daily iodine intake and UIC
[28]: UIC / 0.92 x (0.0009 L/h/kg × 24 h/d) x weight (kg)
= daily iodine intake. The median UIC was 82 μg/L and
the estimated iodine intake was 114 μg/day. The inter-
vention group in this study will be given 400 g of cod
per week, with an approximate iodine content of
100 μg/100 g. This intake will increase the mean
estimated intake of iodine per week from 800 μg to
1200 μg.
Data analysis
The continuous variables will be summarized as mean ±
standard deviation (SD) and the categorical variables will
be described in frequency and percent. The baseline
characteristics will be compared by either the Student t-
test for the continuous variables or χ2-test for the
categorical data. All analyses will initially be done on an
intention-to-treat basis (ITT) and all participants will be
included in the analyses if the relevant outcome vari-
ables have been collected. A per-protocol analysis will
also be conducted for the primary and secondary
outcome if there are a considerable number of protocol
violators. For the primary outcome, a one-way
ANCOVA will be used comparing differences in post-
intervention UIC between the intervention group and
the control group with the pre-intervention UIC as a co-
variate, as it is believed that the post-intervention UIC
will depend, to some degree, on the pre-intervention
UIC. For the secondary outcome, we will use linear re-
gression to compare the mean Bayley-III cognitive score,
the language scores (receptive and expressive separately
and as a composite score) and the motor scores (fine
and gross motor separately and as a composite score)
between the two groups. The Bayley-III scores will be
used on a continuous scale and is expected to be
normally distributed. We will also investigate potential
effect modification by other nutrients and confounding
factors. In the case of unanticipated differences occur-
ring between the intervention and control group, we will
adjust for that/those factor(s) in the analyses for both
the primary and secondary outcome. For the other out-
comes, we will use a variety of statistical approaches
where the data may be used as predictors, mediators or
moderators. These analyses will be based on plans of
analyses for the specific research questions that are
addressed. Multilevel linear modeling will be applied to
assess longitudinally data. Statistically significance will
be set at p < 0.05.
Ethics and dissemination
The trial complies with the Declaration of Helsinki, is ap-
proved by the Regional Committees for Medical and
Health Research Ethics West (2015/879), and is registered
in ClinicalTrials.gov (NCT NCT02610959). Infants must
be especially protected in research since they do not have
the competence to give informed consent and ensure that
their interests are taken proper care of. Written informed
consent was obtained from participants by study investiga-
tors after both written and oral information of the study.
Participants can withdraw from the study at any time
without giving any reason. If a participant wishes to with-
draw from the study, they may require to delete collected
samples and information unless the information is already
included in analyzes or used in scientific publications.
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It is optional to provide biological samples. All tests
are performed in an age adequate way for the infants.
The only invasive procedure is sampling of venous
blood. Analysis have been carefully chosen regarding
sample material to minimize volume drawn from the
infants. Blood sampling will be performed by trained
phlebotomist with experience in blood sampling of
infants and children.
The mother will be informed if she or her infants’ thy-
roid hormone status, iron status or vitamin B12 status is
outside the normal range and be referred to her family
doctor. These parameters will be analyzed in a NS-EN
ISO 15189 accredited medical laboratory and thus ful-
filled the ethical considerations for notification concern-
ing pathological blood test results. Other parameters will
be analyzed at IMR in NS-EN ISO/IEC 17025 laborator-
ies and will thus not fulfill the ethical considerations for
notification concerning pathological blood test results.
In addition, the samples may be analyzed a considerable
time after sampling.
Results from the project will be published in peer-
review journals and presented at international and na-
tional conferences. During the project period, prelimin-
ary results will be presented on conferences and
seminars, both orally and as posters. Progress reports
and statements will be prepared during the study and
after completion, a final report for FHF partners will be
prepared. A summary popular scientific article will be
published in national magazines or newspapers.
Discussion
Insufficient iodine status in pregnancy is a public health
concern. The Norwegian Health Authorities recently
published a report acknowledging the need for urgent
action to secure iodine nutrition in the population [29].
The present trial (Mummy’s Food) is, to our knowledge,
the first RCT intervening pregnant women with iodine
rich fish. Findings from this study are expected to pro-
vide knowledge on whether an increased intake of cod
during pregnancy will improve maternal iodine status,
and if this will have an effect on early child development.
Previous observational studies have found associations
between prenatal iodine nutrition and cognitive func-
tioning in general, as well as on specific developmental
areas such as language [8, 30]. The present study will be
able to confirm these associations between iodine and
development, and test whether the same areas of devel-
opment are impacted by the dietary intervention. This
RCT will also provide valuable research data on other
hypotheses regarding methodological considerations,
maternal and infant nutrition, mental health and infant
development. In case of future funding, the participants
will be asked to complete a developmental testing at
about five years of age.
Trial status
Enrolment has closed with 137 participants. The inter-
vention ended in September 2017. Completion of follow
up at six weeks, three months-, six months, and eleven
months are December 2017, January 2018, April 2018,
and September 2018, respectively. This is protocol
version number 01, issue date 17 January 2018.
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